argenx SE (ARGX)
ARGX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1697862/000155837024003665/0001558370-24-003665-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ARGX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Netherlands |
| IPO year | 2017 |
| SEC CIK | 0001697862 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Netherlands |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $35.5M |
| Net income | -$295.1M |
| Operating income | -$425.0M |
| Net margin | -830.4% |
| Operating margin | -1196.2% |
| Revenue growth | +254.4% |
| Cash | $2.0B |
| Total assets | $4.5B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1661.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-19 |
| Cash and burn | $3.5B cash; operating cash flow $171.3M a quarter. | Report 2025-12-31 |
| Shares outstanding | 61,883,306 (2025-12-31); 60,760,957 a year earlier; 55,395,856 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | EY Accountants B.V., Eindhoven, Netherlands | PCAOB Form AP 2026-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | $1.3B | $685.2M | $3.5B | No debt tags | Needs four quarters | 20-F 2026-03-19 |
| FY 2024 2024-12-31 | Not filed | $833.0M | -$82.7M | $1.5B | No debt tags | Needs four quarters | 20-F 2026-03-19 |
| FY 2023 2023-12-31 | $35.5M | -$295.1M | -$420.3M | $2.0B | $7.2M | $35.5M | 20-F 2024-03-21 |
| FY 2022 2022-12-31 | $10.0M | -$709.6M | -$862.8M | $800.7M | No debt tags | $10.0M | 20-F 2024-03-21 |
| FY 2021 2021-12-31 | $497.3M | -$408.3M | -$606.8M | $1.3B | No debt tags | $497.3M | 20-F 2024-03-21 |
| FY 2020 2020-12-31 | $41.2M | -$608.5M | -$398.5M | $1.2B | No debt tags | $41.2M | 20-F 2023-03-16 |
| FY 2019 2019-12-31 | $78.5M | -$181.2M | $151.6M | $372.2M | No debt tags | $78.5M | 20-F 2022-03-21 |
| FY 2018 2018-12-31 | $21.5M | -$66.6M | Not filed | $321.8M | No debt tags | $21.5M | 20-F 2019-03-26 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2023-07-20 |
| Latest annual report | 20-F | 2026-03-19 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-09 |
Source: SEC EDGAR submissions feed, 298 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.5% |
| 1 month | +19.6% |
| 3 months | +12.0% |
| Year to date | +14.2% |
| 1 year | +7.7% |
| From 52-week high | -9.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MRNA | Moderna Inc. | $215.27 | -3.63% | $87.1B |
| BIIB | Biogen Inc. | $251.65 | -0.69% | $37.2B |
| RVMD | Revolution Medicines Inc. | $166.87 | -3.15% | $36.1B |
| BNTX | BioNTech SE American Depositary Share | $85.26 | -0.40% | $21.4B |
| GILD | Gilead Sciences Inc. | $167.58 | -0.30% | $207.9B |
| NBIX | Neurocrine Biosciences Inc. | $165.31 | -1.25% | $16.7B |
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
| AMGN | Amgen Inc. | $462.32 | -0.72% | $250.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier